We have developed a broad pipeline of nine (9) novel assets with targets spanning the complement cascade. Our lead asset, KP104, is a novel bifunctional biologic that simultaneously and selectively blocks the alternative and terminal pathways and is entering Phase 2 across multiple high-value indications. These assets are investigational agents and have not yet been approved by any Health Authority, such as the FDA.
C5 / Factor H Bifunctional mAb
Renal basket study (IgAN, C3G)
Thrombotic Microangiopathies Secondary to Systemic Lupus Erythematosus
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Long-acting mAB against Clinically Validated Target
Neutrophilic and other autoimmune inflammatory disorders
Long-acting Classical and Lectin Pathway Biologic
KP1020 / KP2050
KP301 is a long-acting mAb against a clinically validated target prominent in neutrophilic and other autoimmune inflammatory disorders. KP501 is a long-acting biologic targeting the classical and lectin pathways, which are implicated in autoantibody-mediated disorders, hemolytic and rheumatologic disorders and is especially applicable to some neurological diseases. We also have bispecific mAbs (KP1020 and KP2050), which have been specifically developed for dry AMD. In addition, we also have other early-stage assets in the pipeline that span across the Classical, Lectin and Alternative pathways.